TY - JOUR
T1 - Erratum to “Arteriopathy after transarterial chemo-lipiodolization for hepatocellular carcinoma” [Diagn. Interv. Imaging 98 (12) (2017) 827–35](S2211568417302784)(10.1016/j.diii.2017.10.010)
AU - Matsui, Y.
AU - Figi, A.
AU - Horikawa, M.
AU - Jahangiri Noudeh, Y.
AU - Tomozawa, Y.
AU - Hashimoto, K.
AU - Kaufman, J. A.
AU - Farsad, K.
N1 - Funding Information:
Activities related to the present article: K.F. received a grant from Guerbet for this study. Activities not related to the present article: Y.M. a grant from Japan Radiological Society supported by Bayer Yakuhin; a consultancy fee from Stryker Japan; a lecture's fee from Terumo Corporation. J.A.K. grants from NIH, WL Gore, and BTG; personal fees from VIVA Physicians, Delcath, MarrowStim and COOK Medical; book royalties and journal editor stipend from Elsevier; section editor stipend from ARRS/AJR; stock ownership in Hatch Medical, Vu Medi, Endoshape, and Veniti; stock options in Javelin Medical, AV Medical, and BIO2 Medical. A.F., M.H., Y.J., Y.T., and K.H. declare that they have no competing interest.
Publisher Copyright:
© 2018
PY - 2018/3
Y1 - 2018/3
N2 - In their article, the authors wish to correct the presentation of Table 1. In addition, the authors wish to complete their disclosure statement. Disclosure of interests: Activities related to the present article: K.F. received a grant from Guerbet for this study. Activities not related to the present article: Y.M. a grant from Japan Radiological Society supported by Bayer Yakuhin; a consultancy fee from Stryker Japan; a lecture's fee from Terumo Corporation. J.A.K. grants from NIH, WL Gore, and BTG; personal fees from VIVA Physicians, Delcath, MarrowStim and COOK Medical; book royalties and journal editor stipend from Elsevier; section editor stipend from ARRS/AJR; stock ownership in Hatch Medical, Vu Medi, Endoshape, and Veniti; stock options in Javelin Medical, AV Medical, and BIO2 Medical. A.F., M.H., Y.J., Y.T., and K.H. declare that they have no competing interest.
AB - In their article, the authors wish to correct the presentation of Table 1. In addition, the authors wish to complete their disclosure statement. Disclosure of interests: Activities related to the present article: K.F. received a grant from Guerbet for this study. Activities not related to the present article: Y.M. a grant from Japan Radiological Society supported by Bayer Yakuhin; a consultancy fee from Stryker Japan; a lecture's fee from Terumo Corporation. J.A.K. grants from NIH, WL Gore, and BTG; personal fees from VIVA Physicians, Delcath, MarrowStim and COOK Medical; book royalties and journal editor stipend from Elsevier; section editor stipend from ARRS/AJR; stock ownership in Hatch Medical, Vu Medi, Endoshape, and Veniti; stock options in Javelin Medical, AV Medical, and BIO2 Medical. A.F., M.H., Y.J., Y.T., and K.H. declare that they have no competing interest.
UR - http://www.scopus.com/inward/record.url?scp=85042905309&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042905309&partnerID=8YFLogxK
U2 - 10.1016/j.diii.2018.01.015
DO - 10.1016/j.diii.2018.01.015
M3 - Comment/debate
C2 - 29456151
AN - SCOPUS:85042905309
SN - 2211-5684
VL - 99
SP - 183
EP - 184
JO - Diagnostic and interventional imaging
JF - Diagnostic and interventional imaging
IS - 3
ER -